Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

253.90DKK
14 Jun 2019
Change (% chg)

kr.-4.00 (-1.55%)
Prev Close
kr.257.90
Open
kr.257.60
Day's High
kr.257.60
Day's Low
kr.252.70
Volume
177,358
Avg. Vol
343,864
52-wk High
kr.477.70
52-wk Low
kr.252.30

Latest Key Developments (Source: Significant Developments)

H. Lundbeck: Jacob Tolstrup Sells 4,000 Shares In Co
Monday, 20 May 2019 08:19am EDT 

May 20 (Reuters) - H Lundbeck A/S ::EXECUTIVE VICE PRESIDENT, COMMERCIAL OPERATIONS JACOB TOLSTRUP SELLS 4,000 SHARES IN CO FOR DKK 266.70 PER SHARE.  Full Article

Health Canada Approves Otsuka & Lundbeck's REXULTI As Adjunctive Treatment Of Major Depressive Disorder
Friday, 22 Feb 2019 02:35pm EST 

Feb 22 (Reuters) - Otsuka::HEALTH CANADA APPROVES OTSUKA AND LUNDBECK'S REXULTI (BREXPIPRAZOLE) AS ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER.  Full Article

Lundbeck And Otsuka Report Phase III Data Evaluating Brexpiprazole
Thursday, 14 Feb 2019 09:00am EST 

Feb 14 (Reuters) - H Lundbeck A/S ::REG-LUNDBECK AND OTSUKA REPORT PHASE III DATA EVALUATING BREXPIPRAZOLE FOR THE TREATMENT OF MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER.REG-LUNDBECK AND OTSUKA REPORT PHASE III DATA EVALUATING BREXPIPRAZOLE FOR THE TREATMENT OF MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER.STUDIES DID NOT MEET PRIMARY ENDPOINT OF STATISTICAL SEPARATION FROM PLACEBO.COMPANIES WILL CONDUCT A THOROUGH ANALYSIS OF STUDY RESULTS TO DETERMINE NEXT STEPS.DURATION OF RANDOMIZED PHASE OF EACH TRIAL WAS 3 WEEKS..IN BOTH STUDIES, PLACEBO EFFECT ON RATING SCALES WAS SUBSTANTIALLY HIGHER THAN ANTICIPATED..RESULTS FROM BIPOLAR 1 DISORDER MANIA STUDIES DO NOT HAVE ANY BEARING ON APPROVED INDICATIONS OF BREXPIPRAZOLE.  Full Article

Teva Announces U.S. Launch Of A Generic Version Of Sabril
Wednesday, 6 Feb 2019 11:13am EST 

Feb 6 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES U.S. LAUNCH OF A GENERIC VERSION OF SABRIL® (VIGABATRIN).TEVA PHARMACEUTICAL INDUSTRIES LTD - LAUNCH OF A GENERIC VERSION OF SABRIL TABLETS, 500 MG IN U.S..  Full Article

Lundbeck Q4 EBIT At DKK 848 Million, Below Expectations
Tuesday, 5 Feb 2019 01:40am EST 

Feb 5 (Reuters) - H Lundbeck A/S ::REG-LUNDBECK REALIZED 8% GROWTH IN REVENUE (LOCAL CURRENCIES) AND 48% GROWTH IN EPS IN 2018.FOR 2019, LUNDBECK EXPECTS REVENUE TO REACH DKK 16.1-16.7 BILLION AND EBIT TO REACH DKK 4.2-4.6 BILLION.PROPOSES TO PAY A DIVIDEND OF DKK 12.00 PER SHARE, EQUAL TO A PAY-OUT RATIO OF 61%.Q4 EBIT DKK 848 MILLION (REUTERS POLL DKK 899 MILLION).MAINTAINING FOCUS ON PROFITABILITY ASPIRING TO AN EBIT-MARGIN OF AT LEAST 25%.WILL SEE INCREASED CAPITAL NEEDS RELATED TO OUR STRATEGIC INITIATIVES.Q4 REVENUE DKK 4.20 BILLION (REUTERS POLL DKK 4.09 BILLION).REVISES DIVIDEND POLICY FROM CURRENT RANGE OF 60-80% OF NET PROFIT TO A RANGE OF 30-60% OF NET PROFIT FROM 2019 ONWARDS."BEST FINANCIAL RESULT EVER AND HAS MORE THAN ACHIEVED FINANCIAL TARGETS SET IN 2016".WILL SEE INCREASED CAPITAL NEEDS RELATED TO STRATEGIC INITIATIVES.REVISES DIVIDEND POLICY FROM CURRENT RANGE OF 60-80% OF NET PROFIT TO A RANGE OF 30-60% OF NET PROFIT FROM 2019 ONWARDS."GIVEN THE VARIETY OF PATHS THAT BUILDING FOR FUTURE GROWTH MAY TAKE, WE WILL NO LONGER PROVIDE LONG TERM TARGETS.".REVISED STRATEGY: ASPIRING TO AN EBIT MARGIN OF AT LEAST 25%.  Full Article

Lundbeck And Otsuka Report Positive Phase II Data For Brexpiprazole And Sertraline
Friday, 30 Nov 2018 03:17am EST 

Nov 30 (Reuters) - H Lundbeck A/S ::REG-LUNDBECK AND OTSUKA REPORT POSITIVE PHASE II DATA FOR THE COMBINATION TREATMENT OF BREXPIPRAZOLE AND SERTRALINE FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER (PTSD).REG-LUNDBECK AND OTSUKA REPORT POSITIVE PHASE II DATA FOR THE COMBINATION TREATMENT OF BREXPIPRAZOLE AND SERTRALINE FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER (PTSD).COMPANIES WILL DISCUSS RESULTS WITH FDA AT AN END-OF-PHASE-II MEETING IN 2019.COMBINATION TREATMENT ARM OF BREXPIPRAZOLE AND SERTRALINE DEMONSTRATED IMPROVEMENT IN SYMPTOMS OF PTSD VERSUS PLACEBO (P<0.01) ON PRIMARY EFFICACY ENDPOINT.EFFICACY OF COMBINATION ARM OVER PLACEBO WAS ALSO SUPPORTED BY DATA FROM MULTIPLE SECONDARY ENDPOINTS.EFFICACY OF COMBINATION ARM OVER PLACEBO WAS ALSO SUPPORTED BY DATA FROM MULTIPLE SECONDARY ENDPOINTS.COMPANIES PLAN TO MEET WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO DISCUSS RESULTS OF PHASE II STUDY.  Full Article

Lundbeck Q3 EBIT Above Estimates At DKK 1.45 Billion
Wednesday, 7 Nov 2018 01:42am EST 

Nov 7 (Reuters) - H Lundbeck A/S ::REG-LUNDBECK REALIZED 12% GROWTH IN REVENUE (LOCAL CURRENCIES) AND 56% GROWTH IN EPS IN 9M 2018. GUIDANCE FOR FY2018 RAISED.REG-LUNDBECK REALIZED 12% GROWTH IN REVENUE (LOCAL CURRENCIES) AND 56% GROWTH IN EPS IN 9M 2018. GUIDANCE FOR FY2018 RAISED.FINANCIAL GUIDANCE FOR 2018 IS RAISED.Q3 EBIT DKK 1.45 BILLION (REUTERS POLL DKK 1.44 BILLION).NOW EXPECTS REVENUE TO REACH DKK 17.7 - 18.1 BILLION AND PROFIT FROM OPERATIONS (EBIT) TO REACH DKK 5.1 - 5.4 BILLION FOR 2018.Q3 REVENUE DKK 4.63 BILLION (REUTERS POLL DKK 4.68 BILLION).SEES PROFIT FROM OPERATIONS (EBIT) TO REACH DKK 5.1 - 5.4 BILLION FOR 2018.FOR THE FULL YEAR 2018 GUIDANCE IS REVISED FOLLOWING BETTER-THAN-EXPECTED SALES PERFORMANCE.SIGNIFICANT DECLINE OF ONFI HAS TO BE EXPECTED STARTING IN Q4 2018 AND CONTINUING INTO 2019.  Full Article

Lundbeck Phase III Study For Lu Af35700 In Treatment-Resistant Schizophrenia Misses Endopoint
Thursday, 25 Oct 2018 10:34am EDT 

Oct 25 (Reuters) - H Lundbeck A/S ::REG-LUNDBECK UPDATES ON CLINICAL PHASE III STUDY FOR LU AF35700 IN TREATMENT-RESISTANT SCHIZOPHRENIA.* LU AF35700 DID NOT SHOW STATISTICAL SUPERIORITY VERSUS CONVENTIONAL THERAPY ON PRIMARY ENDPOINT (CHANGE IN TOTAL PANSS) IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA (TRS).LU AF35700 SHOWED GOOD ANTI-PSYCHOTIC EFFECTS, WAS WELL-TOLERATED AND SAFE AT 10 MG AND 20 MG DOSAGES IN STUDY.FURTHER ANALYSIS OF DATA IS ONGOING.FIRST PHASE III STUDY FOR LU AF35700 DID NOT MEET PRIMARY ENDPOINT OF STATISTICAL SUPERIORITY VERSUS CONVENTIONAL THERAPY.  Full Article

Takeda And Lundbeck Submit New Drug Application (NDA) For Vortioxetine In Japan
Friday, 28 Sep 2018 03:30am EDT 

Sept 28 (Reuters) - Lundbeck ::REG-TAKEDA AND LUNDBECK SUBMIT NEW DRUG APPLICATION (NDA) FOR VORTIOXETINE IN JAPAN FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD).PIVOTAL PHASE III STUDY DEMONSTRATED POSITIVE RESULTS OF VORTIOXETINE AS COMPARED TO PLACEBO FOR TREATMENT OF MDD IN JAPANESE ADULTS.AND TAKEDA WILL CO-COMMERCIALIZE VORTIOXETINE IN JAPAN ONCE APPROVED.PIVOTAL PHASE III STUDY DEMONSTRATED POSITIVE RESULTS OF VORTIOXETINE AS COMPARED TO PLACEBO FOR TREATMENT OF MDD IN JAPANESE ADULTS.  Full Article

Lundbeck To Market Brintellix Strongly In China - Interim CEO
Wednesday, 8 Aug 2018 02:57am EDT 

Aug 8 (Reuters) - H Lundbeck A/S ::SAYS WILL MARKET NEWLY LAUNCHED DRUGS BRINTELLIX AND AZILECT STRONGLY IN CHINA.SAYS THAT SHOULD CONTRIBUTE TO THE EXPECTED DOUBLING OF TOTAL REVENUE IN CHINA WITHIN THE NEXT 5-10 YEARS.SAYS STILL GROWTH IN CIPRALEX/LEXAPRO SALES IN CHINA AND JAPAN EVEN THOUGH THE PATENT ON THE DRUG HAS EXPIRED.  Full Article

Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

BOSTON Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.